Buy Sun Pharma with a target price of Rs 966: Karvy

MUMBAI: Karvy has maintained its Buy rating, with a price target of Rs 966 on Sun Pharma. The companys’s arm URL Pharma has increased the prices by 4 times, while another major player Watson, who has a market share of 31 %, the sales has increased from $ 5 mn in February to $ 13 mn in March. This is in lieu of the drug shortage prevailing as per the USFDA website for Doxcycline.